These include countering neuroinflammation by lowering release of pro-inflammatory cytokines in both BV-2 and adult 5xFAD microglial cells (Fig. 5A), enhancing the microglial clearance of extracellular Aβ1-42 through phagocytosis into acidic cellular compartments in both BV-2 and iPSC derived adult human AD microglial cells (Figs. 5B, 6) and reducing tau phosphorylation in neuroblastoma cells overexpressing human mutant tau (Fig. 5C). The gene discussed is MAPT; the disease is neuroblastoma.